<DOC>
	<DOCNO>NCT03056456</DOCNO>
	<brief_summary>The study conduct participant type 1 diabetes mellitus investigate human body process LY900014 , new blood sugar lower insulin , effect blood sugar level deliver via insulin pump . Side effect tolerability document . The study last 4 11 week participant .</brief_summary>
	<brief_title>A Study LY900014 Administered Insulin Pump Type 1 Diabetes Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Male female participant Type 1 Diabetes Mellitus ( T1DM ) receive insulin therapy via approved insulin pump Have screen body mass index ( BMI ) great 18.5 33.0 kilogram per meter square ( kg/mÂ² ) , inclusive Have medical laboratory test result acceptable study Have episode severe hypoglycemia ( require assistance treatment second party ) past 6 month Have venous access sufficient allow blood sample Have provide write consent willing follow study procedure commit study duration Are currently participate recently participate clinical trial type medical research judge incompatible study Had blood loss 500 milliliter ( mL ) within last month Have know allergy LY900014 , insulin lispro , related compound component study drug formulation Have previously participate withdrawn study Have use health problem medical test result , opinion doctor , could make unsafe participate , could interfere understand result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>